drugset / Trial / NCT05862233
A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous Nephropathy
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the efficacy, safety, pharmacokinetics(PK) ,pharmacodynamics（PD）and anti-drug antibodies（ADA） of MIL62 compared with cyclosporine in participants with primary membranous nephropathy (pMN).
Timeline
- Start
- 2023-06-02
- Primary completion
- 2025-05-13
- Completion
- 2026-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cyclosporine | Peptide | 3.5 mg/kg | Oral |
| Subject | MIL62 | Monoclonal antibody | 1000 mg | Intravenous |